Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
about
Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 TrialSodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusIpragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K StudyEfficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with typeThe Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled TrialDistinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes MellitusClinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phaReal-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.
P2860
Q28074573-C397C18D-F2B2-4686-BF65-83DB8FAB8E95Q30248634-506146DA-7193-46BB-B048-30973153CD10Q33614337-497B56B7-E55C-4743-B25D-FBDA5592CFFAQ33619161-CDEC6BC7-CD20-49AF-A067-CF610B986032Q33763305-3451D34F-9FA9-4321-97CA-BB29577FA410Q33871321-F7DB87B5-6F99-4A63-874B-8901CBF1C332Q35049845-1AEFB14A-7CD6-42FF-A888-C37FF8835D1BQ36232787-A549C9AB-52A0-4895-9C90-C6FAFF5CFA4CQ36429733-2BC59578-B8B6-4E98-94CA-4347D5B17A57Q36756191-80112F2E-7D91-4EB8-9356-5B591F398777Q36843902-E0D2E8AB-4F4E-4C53-A0E8-78606B1FBBF2Q37060855-8127B21D-9D77-4DCC-BA9B-C4CEA9BFECD8Q37251449-06076CDF-2B99-4F6D-93C7-DA90ED9EE5C4Q37257445-4C5AFFC9-F8D8-4150-8A0A-B93BE1EF4B72Q37381227-428D1C2E-2A9C-481B-AF78-8D0D22CCEE59Q37421058-1BB0900A-6CCA-4CBB-92BA-F4EA52453CE0Q37521103-A1C72AC3-E5E7-4783-962D-8F16381EBA05Q38260349-D44788B9-4332-433A-AF1A-AF4476D8EC40Q38340949-CE088F6E-1C1C-43FC-9C23-7B66F68B99D9Q38396879-BEF44300-7F48-4CAB-A2B2-77B552280C97Q38908779-912BB9D4-A531-4A7D-B40E-504EBA559E2AQ39296548-6102CF09-04B2-457E-BBA8-552B058DDFA6Q39540260-9579956A-5AE9-48A0-BF99-1433A4050D70Q40091881-20739A93-2EAF-41AC-83D8-85006560A924Q40606871-0FCE2CED-4583-48BF-81B7-50DE80A61DEDQ41717553-747851B7-92B8-4E14-B300-79CE17446BBDQ41762575-437A60D1-27DF-4D7F-BE82-47FD99E971D9Q43165555-1BA664AD-F40B-470B-BFB7-E5D42582704FQ47995019-E7B62DBE-14DF-4F99-B47E-9A4A5A5CD837Q48234943-82CC8A0A-A524-46BA-96E6-7DB3E649CB9D
P2860
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@ast
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@en
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@nl
type
label
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@ast
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@en
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@nl
prefLabel
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@ast
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@en
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@nl
P2093
P2860
P921
P356
P1476
Randomized, placebo-controlled ...... with type 2 diabetes mellitus
@en
P2093
Atsunori Kashiwagi
Itsuro Nagase
Kenichi Kazuta
Satoshi Yoshida
P2860
P304
P356
10.1111/JDI.12156
P577
2013-11-28T00:00:00Z